Drug discovery is a costly and time-intensive process, with binding free energy calculations between the potential drug ...

The process of separating useful molecules from mixtures of other substances accounts for 15% of the nation's energy, emits ...

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...

Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for ...

Wide areas of the pharmaceutical industry are ripe for enhancement, as examples from the industry’s top innovators reflect.

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.

The Generative AI in Drug Discovery Market was valued at USD 138.5 Million in 2023. It is expected to reach USD 1,435.0 Million by 2033, with a CAGR of 27.1% ...

Enzyme designers in the David Baker lab at the University of Washington in Seattle, from left: Sam Pellock, Anna Lauko, Kiera ...